Skip to content

The ultrasound glioma study.

Ultrasound Navigation Guided Improvement of High Grade Glioma Resection and Quality of Life: a phase III Randomized Controlled Trial. The US-GLIOMA Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28737
Enrollment
Unknown
Registered
2016-08-03
Start date
2016-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

braintumor, glioma hersentumor, glioom

Interventions

The study consists of two treatment arms: non-ultrasound guided glioma resection (conventional treatment) versus ultrasound guided glioma resection (intervention) .

Sponsors

Erasmus Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Individuals between 18-75 years - Newly diagnosed, untreated, contrast enhancing presumed high-grade glioma - KPS ¡Ý 60 - Preoperative intention to perform gross-total resection of the enhancing tumor - Written informed consent conform ICH-GCP

Exclusion criteria

Exclusion criteria: - Tumours crossing the midline basal ganglia, cerebellum, or brain stem prohibiting gross total resection - Multifocal contrast enhancing lesions - Pre-existing neurological deficit (e.g. aphasia, hemiparesis) due to neurological diseases (e.g. stroke) - Inability to give consent because of dysphasia or language barrier

Design outcomes

Primary

MeasureTime frame
The extent of resection will presented as a dichotomous outcome: gross-total resection or sub-total resection. Gross-total resection: No residual contrast enhancement on post-operative MRI scans (within 48 hours); 100% of all contrast enhancing tumor has been resected when compared to initial enhancing tumor on pre-operative MRI scans. Sub-total resection: Residual contrast enhancement on post-operative MRI scans (within 48 hours); <100% of all contrast enhancing tumor has been resected when compared to initial enhancing tumor on pre-operative MRI scans.

Secondary

MeasureTime frame
The extent of resection (%) is a secondary outcome measurement defined as the residual tumor volumes on post-operative MRI studies compared to the operative tumor volume. Patients will be followed for 6 months and the neurological outcome (KPS), Quality of Life (EORTC QLQ-C30,QLQ-BN20), surgery associated neurological deficits (measured 1 month after date of surgery), adverse events and time of survival (days) will be assessed as a secondary outcome measurement.

Contacts

Public ContactFatih Incekara
f.incekara@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)